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Background
Non-Hodgkin’s lymphoma (NHL) is a diverse group of
cancers, elevated in HIV-infected individuals. Kaposi’s
sarcoma-associated herpes virus (KSHV) is found in a
subset of NHL tumors, and could therefore be a cause
of NHL. However, antibody testing for KSHV has lim-
ited sensitivity and specificity and studies have not asso-
ciated KSHV antibodies with NHL odds. KSHV DNA in
serum is a more specific marker of KSHV infection.
Methods
We performed a nested case-control study in the Multi-
center AIDS Cohort Study, including 155 incident NHL
cases occurring between 1984 and 2006 and non-cancer
controls matched by study entry and time at risk. KSHV
DNA was tested in pre-diagnostic serum from within 5
years before diagnosis using real-time quantitative PCR.
Risk factors for NHL were evaluated with conditional
logistic regression models.
Results
NHL cases were significantly more likely to have Kaposi
sarcoma, and had more advanced HIV disease as indi-
cated by lower CD4 cell count at study baseline and
greater reduction in CD4 from baseline to HAART era
than their matched controls (each p<0.01). Detection of
KSHV DNA in pre-diagnostic serum was more common
among NHL cases than controls (14% vs. 6.5%, p=0.03).
However, among cases and controls who had detectable
KSHV DNA, the median KSHV viral load (406 vs. 324,
p=0.39) was comparable. After adjusting for age, baseline
CD4 cell count, and CD4 change, KSHV serum DNA
was no longer significantly associated with odds of NHL
(OR=1.5, 95% CI=0.53-3.9). Similarly null associations
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Table 1 Comparison of KSHV DNA and KSHV seropositivity among 155 HIV-positive incident NHL cases compared to
155 HIV-positive matched controls
OR (95% CI)
N Univariate Multivariate
KSHV serum DNA: ≥1 copy detected 310 2.3 (1.1-5.1) 1.5 (0.53-3.9)
Among subset with serum within 1 year before diagnosis 130 1.2 (0.37-3.9) 0.81 (0.14-4.7)
Among subset without Kaposi sarcoma diagnosis 216 4.0 (1.13-14) 1.9 (0.37-9.6)
Among those developing NHL after AIDS 152 2.0 (0.60-6.6) 2.0 (0.55-7.0)
KSHV antibodies: seroprevalent 252 1.3 (0.68-2.5) 0.85 (0.36-2.0)
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© 2010 D’Souza et al; licensee BioMed Central Ltd.were observed among the subset of participants with
serum within 1 year before diagnosis, by NHL sub-type,
and when stratified by history of Kaposi sarcoma (Table
1). To better match for stage of disease, we performed a
second analysis among 76 NHL cases who developed
NHL after AIDS diagnosis, matching these cases to con-
t r o l sb yt i m es i n c eA I D Sd i a g n o s i s .K S H Vs e r u mD N A
prevalence was similar among these AIDS NHL cases
and matched controls (14% vs. 9.2%, p=0.32). KSHV
seroprevalence was also not associated with odds of NHL.
Conclusions
We found no significant independent association
between KSHV DNA in pre-diagnostic serum with over-
all odds of NHL in this nested case control study. This
research suggests that, similar to KSHV antibodies,
K S H Vs e r u mD N Ad o e sn o th a v ep r e d i c t i v ev a l u ef o r
NHL risk and KSHV is not a primary cause of NHL in
HIV-positive men who have sex with men.
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